Patent Expiry

Patent/Exclusivity Expiry: TLANDO

Drug
TLANDO

Other upcoming events for HALO

Phase 3 ReadoutPhase 3 Topline: Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safet

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: TLANDO — HALO Patent Expiry | BioSniper